Affiliation:
1. Office of Clinical Pharmacology Food and Drug Administration Silver Spring Maryland USA
Abstract
AbstractMany of the conditions for the safe and effective use of new molecular entities (NMEs) are understood at the time of initial drug approval. However, some remaining knowledge gaps can be addressed after drug approval through postmarketing requirements (PMRs) or commitments (PMCs) established by the US Food and Drug Administration (FDA). Our objective was to conduct an assessment of clinical pharmacology–related PMRs and PMCs established at the time of approval and evaluate the impact of fulfilled PMRs and PMCs on prescription information (PI). This analysis included clinical pharmacology–related PMRs and PMCs established for NMEs approved between 2009 and 2020. Of the 1171 PMRs and PMCs, over one‐third were clinical pharmacology–related. Of these, 46% were to evaluate drug interactions, 16% were to evaluate drug dosing in patients with hepatic impairment, and 10% were related to dose. The majority (57%) of PMRs and PMCs were fulfilled at the time of analysis, with a median time to fulfillment of approximately 2.3 years. The majority (94%) of the fulfilled PMRs and PMCs, either with or without a PI revision, resulted in new or modified instructions for use or supported existing instructions for use. This is the first time that clinical pharmacology–related PMRs and PMCs have been catalogued and analyzed to understand their impact on PI. An understanding of the knowledge gaps that exist at the time of drug approval could inform the most effective and efficient methods for evidence generation prior to and after new drug approval.
Subject
Pharmacology (medical),Pharmacology
Reference26 articles.
1. US Food and Drug Administration.Postmarketing Requirements and Commitments: Introduction.https://www.fda.gov/drugs/guidance‐compliance‐regulatory‐information/postmarket‐requirements‐and‐commitments. Accessed October 1 2022.
2. Postmarketing Studies and Clinical Trials — Implementation of Section 505(o)(3) of the Federal Food Drug and Cosmetic Act.https://www.fda.gov/media/131980/download. (2011). Accessed October 1 2022.
3. Elucidating the Impact of Immunogenicity Assessment Postapproval: A Targeted Analysis of Immunogenicity Postmarketing Requirements and Commitments
4. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies
5. Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献